Ordinary Index Rebalancing in the Solactive Pharma & Biotech Opportunity Index | May 2021

In the ordinary rebalance the following composition will be implemented effective open 20.05.2021:

3SBIO INC
ACADIA PHARMACEUTICALS INC
AGIOS PHARMACEUTICALS INC
ALMIRALL SA
ARCUS BIOSCIENCES INC
ARVINAS INC
BAVARIAN NORDIC A/S
BIOMARIN PHARMACEUTICAL INC
CHINA MEDICAL SYSTEM HOLDINGS LTD
CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO LTD
CORCEPT THERAPEUTICS INC
CSPC PHARMACEUTICAL GROUP LTD
EDITAS MEDICINE INC
EISAI
EMERGENT BIOSOLUTIONS INC
EXELIXIS INC
GALAPAGOS NV
IPSEN SA
JAZZ PHARMACEUTICALS PLC
LIGAND PHARMACEUTICALS INC
LUYE PHARMA GROUP LTD
MORPHOSYS AG
NEKTAR THERAPEUTICS
ONENESS BIOTECH CO LTD
RICHTER GEDEON VEGYESZETI GYAR NYILVANOSAN MUKODO RT.
SANTEN PHARMACEUTICAL CO LTD ORD
SAWAI GROUP HOLDINGS CO LTD
SWEDISH ORPHAN BIOVITRUM AB
VIFOR PHARMA AG
XENCOR INC